Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest

Nanomedicine (Lond). 2018 Apr;13(8):887-898. doi: 10.2217/nnm-2017-0395. Epub 2018 Feb 23.

Abstract

Aim: To study the effects of combinational treatment of hyperbaric oxygen (HBO) and nanotemozolomide in glioma.

Materials & methods: Temozolomide (TMZ)-loaded porous silicon nanoparticles (TMZ/PSi NPs) were prepared. In vitro and in vivo evaluations were performed.

Results: The cell uptake of TMZ/PSi NPs could be tracked by autofluorescence of porous silicon. The concentration of oxygen in tumor was improved and the antitumor rate was increased to 84.2% in the TMZ/PSi NPs combined with HBO group. The viability of hypoxia-induced glioma C6 cells was decreased and cell cycle was arrested at G2/M phase in response to TMZ/PSi NPs treatment with HBO compared with continuous treatment with hypoxia.

Conclusion: The combinational treatment of TMZ/PSi NPs and HBO could be a promising therapeutic strategy for glioma.

Keywords: cell cycle; combinational treatment; glioma; hyperbaric oxygen; hypoxia; hypoxia-induced; nanodrug; porous silicon nanoparticle; temozolomide; xenograft.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Cycle Checkpoints / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Glioma / drug therapy*
  • Glioma / pathology
  • Humans
  • Hyperbaric Oxygenation*
  • Mice
  • Nanoparticles / chemistry*
  • Oxygen / therapeutic use
  • Radiation-Sensitizing Agents
  • Silicon / chemistry
  • Temozolomide / chemistry
  • Temozolomide / pharmacology*
  • Xenograft Model Antitumor Assays

Substances

  • Radiation-Sensitizing Agents
  • Oxygen
  • Temozolomide
  • Silicon